Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
renal cell cancer (RCC), atezolizumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results IMmotion-150 (At - all population), 2018 1.19 [0.82; 1.72]
IMmotion-150 (At - PDL1>1%), 2018 1.03 [0.63; 1.68]
1.13 [0.84 ; 1.51 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (At - PDL1>1%), 2018 2 0% 318 moderate not evaluable objective responses (ORR)detailed results IMmotion-150 (At - all population), 2018 0.80 [0.43; 1.48]
IMmotion-150 (At - PDL1>1%), 2018 1.06 [0.46; 2.42]
0.88 [0.54 ; 1.45 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (At - PDL1>1%), 2018 2 0% 318 moderate not evaluable AE (any grade)detailed results IMmotion-150 (At - all population), 2018 0.51 [0.05; 5.72]
0.51 [0.05 ; 5.72 ] IMmotion-150 (At - all population), 2018 1 0% 203 NA not evaluable AE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.30 [0.17; 0.53]
0.30 [0.17 ; 0.53 ] IMmotion-150 (At - all population), 2018 1 0% 203 NA not evaluable AE leading to death (grade 5)detailed results IMmotion-150 (At - all population), 2018 0.97 [0.13; 7.02]
0.97 [0.13 ; 7.02 ] IMmotion-150 (At - all population), 2018 1 0% 203 NA not evaluable TRAE (any grade)detailed results IMmotion-150 (At - all population), 2018 0.21 [0.07; 0.65]
0.21 [0.07 ; 0.65 ] IMmotion-150 (At - all population), 2018 1 0% 203 NA not evaluable TRAE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.15 [0.08; 0.29]
0.15 [0.08 ; 0.29 ] IMmotion-150 (At - all population), 2018 1 0% 203 NA not evaluable TRAE leading to death (grade 5)detailed results IMmotion-150 (At - all population), 2018 0.24 [0.01; 5.37]
0.24 [0.01 ; 5.37 ] IMmotion-150 (At - all population), 2018 1 0% 203 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.98 [0.02; 49.90]
0.98 [0.02 ; 49.90 ] IMmotion-150 (At - all population), 2018 1 0% 204 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.98 [0.02; 49.90]
0.98 [0.02 ; 49.90 ] IMmotion-150 (At - all population), 2018 1 0% 204 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-20 18:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 10,93,79,178,152,80
- treatments: 361
